Ascendis Pharma A/S (NASDAQ:ASND) Now Covered by Analysts at Morgan Stanley

Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note released on Thursday, Marketbeat reports. The firm issued an overweight rating and a $250.00 price objective on the biotechnology company’s stock.

A number of other research firms also recently weighed in on ASND. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Wedbush raised their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a research note on Friday, May 2nd. Bank of America raised their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a “buy” rating in a research note on Monday, June 9th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Finally, JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $220.67.

Ascendis Pharma A/S Trading Up 0.6%

Shares of ASND stock opened at $174.07 on Thursday. The stock has a market cap of $10.64 billion, a P/E ratio of -27.72 and a beta of 0.38. The stock has a 50 day simple moving average of $167.68 and a 200 day simple moving average of $152.26. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock worth $55,000 after buying an additional 273 shares in the last quarter. Quarry LP bought a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $96,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company’s stock worth $138,000 after buying an additional 664 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.